Form 4: TELA Bio CTO Paul Talmo Granted New Equity Awards

TELA Bio's Chief Technology Officer, Paul Talmo, reported the acquisition of restricted stock units and stock options, alongside shares withheld for tax obligations.

Summary

• Paul Talmo, Chief Technology Officer of TELA Bio, Inc., reported the acquisition of 57,000 Restricted Stock Units (RSUs) on February 20, 2026.
• These RSUs will vest in four equal annual installments, commencing on February 20, 2027, contingent on continuous service.
• Talmo also acquired 85,000 stock options on February 20, 2026, with an exercise price of $0.717.
• The stock options vest 25% on February 20, 2027, with the remaining 75% vesting in equal monthly installments over the subsequent 36 calendar months, subject to continued service.
• Shares of Common Stock were disposed of to satisfy tax withholding obligations upon RSU vesting: 3,385 shares at $0.7174 on February 21, 2026, and 4,061 shares at $0.766 on February 23, 2026.
• Following these transactions, Talmo beneficially owns 173,436 shares of Common Stock and 85,000 derivative stock options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, primarily for the executive, as it represents a significant compensation package. For the company, it's a neutral to slightly positive event, as it aligns executive incentives with long-term shareholder value, a standard corporate governance practice.

Positives

• The grant of 57,000 Restricted Stock Units (RSUs) aligns the Chief Technology Officer's long-term interests with those of shareholders.
• The acquisition of 85,000 stock options provides a performance-based incentive for the Chief Technology Officer, linking compensation to future stock price appreciation.

Negatives

• A total of 7,446 shares of Common Stock were withheld by the Issuer to cover applicable tax obligations related to RSU vesting, representing a disposition of shares.

Future Outlook

The vesting schedules for both the Restricted Stock Units and stock options extend several years into the future, indicating an expectation of continued service from the Chief Technology Officer and a long-term incentive structure.

Industry Context

StockSavvy.ai notes that the grant of Restricted Stock Units and stock options to a Chief Technology Officer is a standard practice in the biotechnology and medical device industries. This form of equity compensation is widely used to attract, retain, and incentivize key executives by aligning their financial interests with the long-term performance of the company. It reflects a common approach to executive remuneration in growth-oriented sectors.

Comparison to Industry Standards

• The structure of equity grants, combining RSUs and stock options with multi-year vesting schedules, is consistent with compensation practices observed at comparable medical technology companies such as Integra LifeSciences Holdings Corporation (IART) or Organogenesis Holdings Inc. (ORGO).
• The specific vesting terms, including a one-year cliff for initial vesting followed by monthly or annual installments, are typical for executive compensation packages designed to promote long-term retention and performance.

Stakeholder Impact

• Shareholders: The grants represent a standard form of executive compensation, potentially leading to minor dilution over time as shares vest, but also aiming to align management's interests with long-term shareholder value.
• Employees: The compensation package for a key executive may serve as a benchmark or motivator for other employees, particularly in leadership roles.
• Management (Paul Talmo): Significant increase in potential future equity ownership, providing strong incentives for long-term performance and retention.

Next Steps

• Continued service of the Chief Technology Officer through the specified vesting dates for RSUs and stock options.
• Annual vesting of RSUs beginning February 20, 2027.
• Monthly vesting of stock options following the initial 25% vesting on February 20, 2027.

Key Dates

Keywords

TELA Bio, Paul Talmo, Chief Technology Officer, Restricted Stock Units, RSU, Stock Options, Executive Compensation, Insider Transaction, Form 4